Selected phase 3 trials for FDA-approved frontline regimens for unfit patients
| Trial . | Duration . | ORR, % . | PFS, % . |
|---|---|---|---|
| RESONATE-2*: chlorambucil33,34 | Continuous | 37 | 12 (est. 60 mo) |
| RESONATE-2*: ibrutinib33,34 | Continuous | 92 | 70 (est. 60 mo) |
| A041202: IR35 | Continuous ibrutinib; 6 cycles of rituximab | 94 | 88 (est. 24 mo) |
| A041202: Ibrutinib35 | Continuous | 93 | 87 (est. 24 mo) |
| A041202: BR35 | Up to 6 cycles | 81 | 73 (est. 24 mo) |
| iLLUMINATE: IO36 | Continuous | 88 | 79 (est. 30 mo) |
| iLLUMINATE: ChlO36 | Up to 6 cycles | 73 | 31 (est. 30 mo) |
| CLL14: VenO44 | Obinutuzumab 6 cycles, venetoclax 12 cycles | 84.7 | 82 (est. 36 mo) |
| CLL14: ChlO44 | Obinutuzumab 6 cycles, chlorambucil 12 cycles | 71.2 | 50 (est. 36 mo) |
| ELEVATE-TN: acalabrutinib40 | Continuous | 86 | 87 (est. 24 mo) |
| ELEVATE-TN: AO40 | Continuous | 94 | 93 (est. 24 mo) |
| ELEVATE-TN: ChlO40 | Up to 6 cycles | 79 | 47 (est. 24 mo) |
| Trial . | Duration . | ORR, % . | PFS, % . |
|---|---|---|---|
| RESONATE-2*: chlorambucil33,34 | Continuous | 37 | 12 (est. 60 mo) |
| RESONATE-2*: ibrutinib33,34 | Continuous | 92 | 70 (est. 60 mo) |
| A041202: IR35 | Continuous ibrutinib; 6 cycles of rituximab | 94 | 88 (est. 24 mo) |
| A041202: Ibrutinib35 | Continuous | 93 | 87 (est. 24 mo) |
| A041202: BR35 | Up to 6 cycles | 81 | 73 (est. 24 mo) |
| iLLUMINATE: IO36 | Continuous | 88 | 79 (est. 30 mo) |
| iLLUMINATE: ChlO36 | Up to 6 cycles | 73 | 31 (est. 30 mo) |
| CLL14: VenO44 | Obinutuzumab 6 cycles, venetoclax 12 cycles | 84.7 | 82 (est. 36 mo) |
| CLL14: ChlO44 | Obinutuzumab 6 cycles, chlorambucil 12 cycles | 71.2 | 50 (est. 36 mo) |
| ELEVATE-TN: acalabrutinib40 | Continuous | 86 | 87 (est. 24 mo) |
| ELEVATE-TN: AO40 | Continuous | 94 | 93 (est. 24 mo) |
| ELEVATE-TN: ChlO40 | Up to 6 cycles | 79 | 47 (est. 24 mo) |
Did not enroll patients with del17p.